The European Union’s antitrust watchdog will launch an in-depth probe into China National Chemical’s plan to buy Syngenta to determine if the deal would lower competition for crop-protection products.
The investigation will focus on whether combining Swiss-based Syngenta, which sells about one-fifth of the world’s pesticides, with a ChemChina-owned company that supplies generic alternatives would leave farmers with higher chemical costs or fewer available products, according to the EU.
The move was expected after Syngenta signaled earlier this week that its sale would likely be delayed until early 2017. It reflects the level of scrutiny by antitrust authorities for farm-sector deals at a time when farmers in Europe and the US grapple with low grain prices following consecutive bumper crops that swelled global supplies.
The European Commission, the EU’s executive arm, said Friday that Syngenta and Adama Agricultural Solutions, an Israeli maker of generic pesticides that is controlled by ChemChina, had “strong overlapping portfolios” of crop-protection products such as herbicides and insecticides. The commission set a deadline for March 15 to complete its review.
“We need to carefully assess whether the proposed merger would lead to higher prices or a reduced choice for farmers,” said EU Antitrust Chief Margrethe Vestager.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas